Draper and Partners Awarded ARPA-H Funding to End Cold-Chain Dependence for Cell Therapies and Cancer Drugs

Positive

AI Analysis

Summary

Draper received a $7.3 million OTA from ARPA-H to develop methods for producing cell therapies and cancer drugs without cold-chain dependence as part of the BioStabilization Systems program.

Outcome Details

Draper awarded $7.3 million OTA from ARPA-H for Phase 1 of BioStabilization Systems program

Importance:4/10

Sentiment:

0.70

fundingcell therapycold chainARPA-Hdrug stability

Related Companies

$HIT $DMIIR

Read the original article

Published by PR Newswire Biotech on October 7, 2026 4:15 PM

Read Original